KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Research & Development (2016 - 2025)

Historic Research & Development for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $2.3 billion.

  • AbbVie's Research & Development rose 887.32% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.3 billion, marking a year-over-year increase of 6730.87%. This contributed to the annual value of $12.8 billion for FY2024, which is 6665.8% up from last year.
  • As of Q3 2025, AbbVie's Research & Development stood at $2.3 billion, which was up 887.32% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, AbbVie's Research & Development ranged from a high of $6.8 billion in Q4 2024 and a low of $1.5 billion during Q1 2022
  • For the 5-year period, AbbVie's Research & Development averaged around $2.1 billion, with its median value being $1.8 billion (2021).
  • The largest annual percentage gain for AbbVie's Research & Development in the last 5 years was 25153.09% (2024), contrasted with its biggest fall of 1540.14% (2024).
  • Quarter analysis of 5 years shows AbbVie's Research & Development stood at $1.8 billion in 2021, then dropped by 2.03% to $1.8 billion in 2022, then grew by 7.65% to $1.9 billion in 2023, then skyrocketed by 251.53% to $6.8 billion in 2024, then tumbled by 65.77% to $2.3 billion in 2025.
  • Its last three reported values are $2.3 billion in Q3 2025, $2.1 billion for Q2 2025, and $2.1 billion during Q1 2025.